Financhill
Sell
34

HCAT Quote, Financials, Valuation and Earnings

Last price:
$7.11
Seasonality move :
-12.17%
Day range:
$6.75 - $7.25
52-week range:
$5.42 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.39x
P/B ratio:
1.22x
Volume:
936.5K
Avg. volume:
571.5K
1-year change:
-21.2%
Market cap:
$432M
Revenue:
$295.9M
EPS (TTM):
-$1.35

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HCAT
Health Catalyst
$76.4M $0.09 7.55% -- --
ADUS
Addus HomeCare
$289.5M $1.28 1.35% 12.56% $137.82
AMED
Amedisys
$588.8M $1.17 4.55% 80.17% --
OPCH
Option Care Health
$1.2B $0.32 12.91% 6.29% --
OPRX
OptimizeRx
$25M $0.06 4.13% -69.17% $10.36
RHE
Regional Health Properties
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HCAT
Health Catalyst
$7.10 -- $432M -- $0.00 0% 1.39x
ADUS
Addus HomeCare
$131.40 $137.82 $2.4B 30.07x $0.00 0% 1.95x
AMED
Amedisys
$84.49 -- $2.8B 33.53x $0.00 0% 1.20x
OPCH
Option Care Health
$22.91 -- $3.9B 19.25x $0.00 0% 0.84x
OPRX
OptimizeRx
$4.89 $10.36 $90.1M -- $0.00 0% 1.01x
RHE
Regional Health Properties
$1.51 -- $2.8M 0.13x $0.00 0% 0.16x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HCAT
Health Catalyst
49.29% 1.912 69.66% 1.36x
ADUS
Addus HomeCare
-- 1.713 -- 2.03x
AMED
Amedisys
24.97% -0.159 11.88% 1.12x
OPCH
Option Care Health
43.8% 2.260 20.87% 1.19x
OPRX
OptimizeRx
23.56% 4.188 24.93% 2.93x
RHE
Regional Health Properties
105.42% -0.982 206.21% 0.51x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HCAT
Health Catalyst
$34M -$13.7M -12.86% -21.76% -11.89% $1.8M
ADUS
Addus HomeCare
$92.2M $26M 8.42% 9.24% 9.61% $46.6M
AMED
Amedisys
$250.1M $47M 5.39% 7.23% 6.26% $104M
OPCH
Option Care Health
$256.7M $85.1M 8.33% 14.65% 6.72% $150.7M
OPRX
OptimizeRx
$13.4M -$1.1M -16.25% -20.12% -39.5% $1.7M
RHE
Regional Health Properties
$1.9M -$300K -5.98% -489.72% -7.22% -$147K

Health Catalyst vs. Competitors

  • Which has Higher Returns HCAT or ADUS?

    Addus HomeCare has a net margin of -19.29% compared to Health Catalyst's net margin of 6.96%. Health Catalyst's return on equity of -21.76% beat Addus HomeCare's return on equity of 9.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCAT
    Health Catalyst
    44.58% -$0.24 $700.1M
    ADUS
    Addus HomeCare
    31.82% $1.10 $947.6M
  • What do Analysts Say About HCAT or ADUS?

    Health Catalyst has a consensus price target of --, signalling upside risk potential of 60.69%. On the other hand Addus HomeCare has an analysts' consensus of $137.82 which suggests that it could grow by 4.89%. Given that Health Catalyst has higher upside potential than Addus HomeCare, analysts believe Health Catalyst is more attractive than Addus HomeCare.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCAT
    Health Catalyst
    0 0 0
    ADUS
    Addus HomeCare
    8 0 0
  • Is HCAT or ADUS More Risky?

    Health Catalyst has a beta of 1.315, which suggesting that the stock is 31.457% more volatile than S&P 500. In comparison Addus HomeCare has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.53%.

  • Which is a Better Dividend Stock HCAT or ADUS?

    Health Catalyst has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Health Catalyst pays -- of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCAT or ADUS?

    Health Catalyst quarterly revenues are $76.4M, which are smaller than Addus HomeCare quarterly revenues of $289.8M. Health Catalyst's net income of -$14.7M is lower than Addus HomeCare's net income of $20.2M. Notably, Health Catalyst's price-to-earnings ratio is -- while Addus HomeCare's PE ratio is 30.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Catalyst is 1.39x versus 1.95x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCAT
    Health Catalyst
    1.39x -- $76.4M -$14.7M
    ADUS
    Addus HomeCare
    1.95x 30.07x $289.8M $20.2M
  • Which has Higher Returns HCAT or AMED?

    Amedisys has a net margin of -19.29% compared to Health Catalyst's net margin of 2.88%. Health Catalyst's return on equity of -21.76% beat Amedisys's return on equity of 7.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCAT
    Health Catalyst
    44.58% -$0.24 $700.1M
    AMED
    Amedisys
    42.56% $0.51 $1.6B
  • What do Analysts Say About HCAT or AMED?

    Health Catalyst has a consensus price target of --, signalling upside risk potential of 60.69%. On the other hand Amedisys has an analysts' consensus of -- which suggests that it could grow by 14.02%. Given that Health Catalyst has higher upside potential than Amedisys, analysts believe Health Catalyst is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCAT
    Health Catalyst
    0 0 0
    AMED
    Amedisys
    0 0 0
  • Is HCAT or AMED More Risky?

    Health Catalyst has a beta of 1.315, which suggesting that the stock is 31.457% more volatile than S&P 500. In comparison Amedisys has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.385%.

  • Which is a Better Dividend Stock HCAT or AMED?

    Health Catalyst has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Health Catalyst pays -- of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCAT or AMED?

    Health Catalyst quarterly revenues are $76.4M, which are smaller than Amedisys quarterly revenues of $587.7M. Health Catalyst's net income of -$14.7M is lower than Amedisys's net income of $16.9M. Notably, Health Catalyst's price-to-earnings ratio is -- while Amedisys's PE ratio is 33.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Catalyst is 1.39x versus 1.20x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCAT
    Health Catalyst
    1.39x -- $76.4M -$14.7M
    AMED
    Amedisys
    1.20x 33.53x $587.7M $16.9M
  • Which has Higher Returns HCAT or OPCH?

    Option Care Health has a net margin of -19.29% compared to Health Catalyst's net margin of 4.21%. Health Catalyst's return on equity of -21.76% beat Option Care Health's return on equity of 14.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCAT
    Health Catalyst
    44.58% -$0.24 $700.1M
    OPCH
    Option Care Health
    20.08% $0.31 $2.5B
  • What do Analysts Say About HCAT or OPCH?

    Health Catalyst has a consensus price target of --, signalling upside risk potential of 60.69%. On the other hand Option Care Health has an analysts' consensus of -- which suggests that it could grow by 31.43%. Given that Health Catalyst has higher upside potential than Option Care Health, analysts believe Health Catalyst is more attractive than Option Care Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCAT
    Health Catalyst
    0 0 0
    OPCH
    Option Care Health
    5 0 0
  • Is HCAT or OPCH More Risky?

    Health Catalyst has a beta of 1.315, which suggesting that the stock is 31.457% more volatile than S&P 500. In comparison Option Care Health has a beta of 1.332, suggesting its more volatile than the S&P 500 by 33.16%.

  • Which is a Better Dividend Stock HCAT or OPCH?

    Health Catalyst has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Health Catalyst pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCAT or OPCH?

    Health Catalyst quarterly revenues are $76.4M, which are smaller than Option Care Health quarterly revenues of $1.3B. Health Catalyst's net income of -$14.7M is lower than Option Care Health's net income of $53.9M. Notably, Health Catalyst's price-to-earnings ratio is -- while Option Care Health's PE ratio is 19.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Catalyst is 1.39x versus 0.84x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCAT
    Health Catalyst
    1.39x -- $76.4M -$14.7M
    OPCH
    Option Care Health
    0.84x 19.25x $1.3B $53.9M
  • Which has Higher Returns HCAT or OPRX?

    OptimizeRx has a net margin of -19.29% compared to Health Catalyst's net margin of -42.82%. Health Catalyst's return on equity of -21.76% beat OptimizeRx's return on equity of -20.12%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCAT
    Health Catalyst
    44.58% -$0.24 $700.1M
    OPRX
    OptimizeRx
    63.11% -$0.50 $149.7M
  • What do Analysts Say About HCAT or OPRX?

    Health Catalyst has a consensus price target of --, signalling upside risk potential of 60.69%. On the other hand OptimizeRx has an analysts' consensus of $10.36 which suggests that it could grow by 111.8%. Given that OptimizeRx has higher upside potential than Health Catalyst, analysts believe OptimizeRx is more attractive than Health Catalyst.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCAT
    Health Catalyst
    0 0 0
    OPRX
    OptimizeRx
    4 1 0
  • Is HCAT or OPRX More Risky?

    Health Catalyst has a beta of 1.315, which suggesting that the stock is 31.457% more volatile than S&P 500. In comparison OptimizeRx has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.097%.

  • Which is a Better Dividend Stock HCAT or OPRX?

    Health Catalyst has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Health Catalyst pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCAT or OPRX?

    Health Catalyst quarterly revenues are $76.4M, which are larger than OptimizeRx quarterly revenues of $21.3M. Health Catalyst's net income of -$14.7M is lower than OptimizeRx's net income of -$9.1M. Notably, Health Catalyst's price-to-earnings ratio is -- while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Catalyst is 1.39x versus 1.01x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCAT
    Health Catalyst
    1.39x -- $76.4M -$14.7M
    OPRX
    OptimizeRx
    1.01x -- $21.3M -$9.1M
  • Which has Higher Returns HCAT or RHE?

    Regional Health Properties has a net margin of -19.29% compared to Health Catalyst's net margin of -23.24%. Health Catalyst's return on equity of -21.76% beat Regional Health Properties's return on equity of -489.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    HCAT
    Health Catalyst
    44.58% -$0.24 $700.1M
    RHE
    Regional Health Properties
    44.9% -$0.52 $43.9M
  • What do Analysts Say About HCAT or RHE?

    Health Catalyst has a consensus price target of --, signalling upside risk potential of 60.69%. On the other hand Regional Health Properties has an analysts' consensus of -- which suggests that it could grow by 330.46%. Given that Regional Health Properties has higher upside potential than Health Catalyst, analysts believe Regional Health Properties is more attractive than Health Catalyst.

    Company Buy Ratings Hold Ratings Sell Ratings
    HCAT
    Health Catalyst
    0 0 0
    RHE
    Regional Health Properties
    0 0 0
  • Is HCAT or RHE More Risky?

    Health Catalyst has a beta of 1.315, which suggesting that the stock is 31.457% more volatile than S&P 500. In comparison Regional Health Properties has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.446%.

  • Which is a Better Dividend Stock HCAT or RHE?

    Health Catalyst has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Health Catalyst pays -- of its earnings as a dividend. Regional Health Properties pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HCAT or RHE?

    Health Catalyst quarterly revenues are $76.4M, which are larger than Regional Health Properties quarterly revenues of $4.2M. Health Catalyst's net income of -$14.7M is lower than Regional Health Properties's net income of -$982K. Notably, Health Catalyst's price-to-earnings ratio is -- while Regional Health Properties's PE ratio is 0.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Health Catalyst is 1.39x versus 0.16x for Regional Health Properties. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HCAT
    Health Catalyst
    1.39x -- $76.4M -$14.7M
    RHE
    Regional Health Properties
    0.16x 0.13x $4.2M -$982K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock